{"componentChunkName":"component---src-templates-chapter-level-1-chapter-level-1-tsx","path":"/topics/nsaids-prescribing-issues/have-i-got-the-right-topic/","result":{"pageContext":{"chapter":{"id":"e5927ea9-133a-5f9b-a357-a61c0992b6c6","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","depth":1,"htmlHeader":"<!-- begin field 9e9f2920-974d-491d-859d-b48690d887c4 --><h1>Have I got the right topic?</h1><!-- end field 9e9f2920-974d-491d-859d-b48690d887c4 -->","summary":null,"htmlStringContent":"<!-- begin item 0740077e-2397-4feb-b87c-13434b55dc88 --><!-- begin field d7a9923d-7d8a-4224-805c-acbd00893e69 --><p>From age 1 month onwards.</p><!-- end field d7a9923d-7d8a-4224-805c-acbd00893e69 --><!-- begin field abc474f4-eaae-41cd-94ad-14452a3a64d4 --><p>This CKS topic is largely based on the Medicines and Healthcare products Regulatory Agency (MHRA) drug safety updates <em>Diclofenac: new contraindications and warnings </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/nsaids-prescribing-issues/references/\">MHRA, 2014</a>], <em>High-dose ibuprofen (≥2400mg/day): small increase in cardiovascular risk </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/nsaids-prescribing-issues/references/\">MHRA, 2015a</a>], and <em>Non-steroidal anti-inflammatory drugs (NSAIDs): reminder on renal failure and impairment </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/nsaids-prescribing-issues/references/\">MHRA, 2009</a>], the European Society of Cardiology (ESC) review and position paper <em>Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/nsaids-prescribing-issues/references/\">Schmidt, 2016</a>], the European Medicines Agency (EMA) review <em>Updated advice on the use of high-dose ibuprofen </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/nsaids-prescribing-issues/references/\">EMA, 2015</a>], a U.S. Food and Drug Administration (FDA) drug safety communication <em>FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/nsaids-prescribing-issues/references/\">FDA, 2015</a>], expert opinion in a medical textbook <em>Medical Pharmacology at a glance</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/nsaids-prescribing-issues/references/\">Neal, 2015</a>], and a narrative review <em>Non-steroidal anti-inflammatory drugs (NSAIDs) </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/nsaids-prescribing-issues/references/\">O&#39;Day, 2013</a>], the <em>British National Formulary</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/nsaids-prescribing-issues/references/\">BNF 75, 2018</a>], and the manufacturers' Summaries of Product Characteristics for Diclomax retard [<a class=\"bibliography-reference internal-reference\" href=\"/topics/nsaids-prescribing-issues/references/\">ABPI, 2018a</a>], ibuprofen [<a class=\"bibliography-reference internal-reference\" href=\"/topics/nsaids-prescribing-issues/references/\">ABPI, 2018b</a>], naproxen [<a class=\"bibliography-reference internal-reference\" href=\"/topics/nsaids-prescribing-issues/references/\">ABPI, 2018c</a>], celecoxib [<a class=\"bibliography-reference internal-reference\" href=\"/topics/nsaids-prescribing-issues/references/\">ABPI, 2018d</a>], and etoricoxib [<a class=\"bibliography-reference internal-reference\" href=\"/topics/nsaids-prescribing-issues/references/\">ABPI, 2018e</a>].</p><p>This CKS topic outlines the factors that need to be considered when prescribing a nonsteroidal anti-inflammatory drug (NSAID), including the risk of gastrointestinal and cardiovascular adverse effects and how to manage these risks. </p><p>This CKS topic does not cover the management of people with upper gastrointestinal ulcers associated with NSAIDs, or the management of people with dyspepsia in people taking NSAIDs. There are separate CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/dyspepsia-proven-peptic-ulcer/\">Dyspepsia - proven peptic ulcer</a>), <a class=\"topic-reference external-reference\" href=\"/topics/dyspepsia-proven-functional/\">Dyspepsia - proven functional</a>, <a class=\"topic-reference external-reference\" href=\"/topics/dyspepsia-proven-gord/\"> Dyspepsia - proven GORD</a>, <a class=\"topic-reference external-reference\" href=\"/topics/dyspepsia-unidentified-cause/\">Dyspepsia - unidentified cause</a>, and the management of low-dose aspirin is discussed in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/antiplatelet-treatment/\">Antiplatelet treatment</a>.</p><p>This CKS topic does not cover the indications and effectiveness of NSAIDs. These are addressed in separate CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/ankylosing-spondylitis/\">Ankylosing spondylitis</a>, <a class=\"topic-reference external-reference\" href=\"/topics/back-pain-low-without-radiculopathy/\">Back pain - low (without radiculopathy)</a>, <a class=\"topic-reference external-reference\" href=\"/topics/dysmenorrhoea/\">Dysmenorrhoea</a>, <a class=\"topic-reference external-reference\" href=\"/topics/endometriosis/\">Endometriosis</a>, <a class=\"topic-reference external-reference\" href=\"/topics/gout/\">Gout</a>, <a class=\"topic-reference external-reference\" href=\"/topics/headache-medication-overuse/\">Headache - medication overuse</a>, <a class=\"topic-reference external-reference\" href=\"/topics/menorrhagia/\">Menorrhagia</a>, <a class=\"topic-reference external-reference\" href=\"/topics/migraine/\">Migraine</a>, <a class=\"topic-reference external-reference\" href=\"/topics/neck-pain-acute-torticollis/\">Neck pain - acute torticollis</a>, <a class=\"topic-reference external-reference\" href=\"/topics/neck-pain-cervical-radiculopathy/\">Neck pain - cervical radiculopathy</a>, <a class=\"topic-reference external-reference\" href=\"/topics/neck-pain-non-specific/\">Neck pain - non-specific</a>, <a class=\"topic-reference external-reference\" href=\"/topics/neck-pain-whiplash-injury/\">Neck pain - whiplash injury</a>, <a class=\"topic-reference external-reference\" href=\"/topics/osteoarthritis/\">Osteoarthritis</a>, <a class=\"topic-reference external-reference\" href=\"/topics/palliative-cancer-care-pain/\">Palliative cancer care - pain</a>, <a class=\"topic-reference external-reference\" href=\"/topics/rheumatoid-arthritis/\">Rheumatoid arthritis</a>, <a class=\"topic-reference external-reference\" href=\"/topics/sciatica-lumbar-radiculopathy/\">Sciatica (lumbar radiculopathy)</a>, <a class=\"topic-reference external-reference\" href=\"/topics/sprains-strains/\">Sprains and strains</a>, and <a class=\"topic-reference external-reference\" href=\"/topics/superficial-vein-thrombosis-superficial-thrombophlebitis/\">Thrombophlebitis - superficial</a>.</p><p>The target audience for this CKS topic is healthcare professionals working within the NHS in the UK, and providing first contact or primary healthcare.</p><!-- end field abc474f4-eaae-41cd-94ad-14452a3a64d4 --><!-- end item 0740077e-2397-4feb-b87c-13434b55dc88 -->","topic":{"id":"ceac2e33-6fd9-5bdf-a103-bdeff3e6efe7","topicId":"5e29889f-d8f4-4f4e-9bce-78c262cd5e62","topicName":"NSAIDs - prescribing issues","slug":"nsaids-prescribing-issues","lastRevised":"Last revised in April 2020","chapters":[{"id":"81e21dc7-3fa3-5a27-a799-d7e553aa1b01","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"e5927ea9-133a-5f9b-a357-a61c0992b6c6","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"f8ed8fe1-df7d-5125-937f-2d1e3501233c","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"f6920c2a-03f6-5506-aec1-3fdde89dd2f7","slug":"changes","fullItemName":"Changes"},{"id":"7e3ebe71-e455-5372-ae22-416ce6a0b71a","slug":"update","fullItemName":"Update"}]},{"id":"acb8e014-609e-5dc6-9f65-30c1458821c4","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"93d7bec8-79d3-5e43-b717-afe25c73d3ca","slug":"goals","fullItemName":"Goals"},{"id":"80a6271f-7ea5-5a98-902b-a008dc09f1ee","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"6782e03f-1ef7-5af4-86c0-eb675a202116","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"fcacc99e-0dfb-5679-b56f-f8205eba1edc","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"15a07f25-5af2-57a1-a7ac-048177f2fb99","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"39c204ac-0dfe-5334-ba6a-72f81053bd3d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"9ce106c0-0dc6-5564-9353-be22c8fc1ed5","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"0cc396a7-37bb-55ac-a9b6-83b76805f342","slug":"definition","fullItemName":"Definition"},{"id":"d742f98e-351a-50ba-bc7a-d0ecc0e7689d","slug":"mode-of-action","fullItemName":"Mode of action"},{"id":"93f69297-618f-59f0-b4d4-f6e50bdf5467","slug":"classification","fullItemName":"Classification"}]},{"id":"6537c6fb-b310-5291-98df-d01a4e961e7e","fullItemName":"Management","slug":"management","subChapters":[{"id":"f7cf8186-98aa-5332-bbd7-7ac7f7c5748e","slug":"nsaids-prescribing-issues","fullItemName":"Scenario: NSAIDs  prescribing issues"}]},{"id":"1e3b7407-6a49-5511-bff4-c0f0e8e7b22e","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"56eccf0e-4660-56df-8972-3fc937ad78b7","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"80126798-6f53-5ceb-b2d7-d2c5adf206da","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0e838f63-dbcc-5df4-ba98-67f8c94448ed","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"179593fd-6f34-5834-a706-a5b7abb725a3","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"b21e3781-fcad-52bd-b0b3-0b7f267e817d","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"ece91260-71c4-51d6-bc77-400de18b4802","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"dedb4c68-d2e7-53bb-81ef-03a9600c383d","fullItemName":"References","slug":"references","subChapters":[]}]},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}